1 Evolution in Thrombosis Management MODULE 1: Stroke Prevention in Atrial Fibrillation - Dr. Ben Bell MODULE 2: Clinical Challenges in the Treatment of VTE - Dr. Menaka Pai
2 Learning Objectives After attending this session, participants will be better able to: Utilize guideline based strategies for stroke prevention in atrial fibrillation; Implement strategies for the management of acute VTE and for the prevention of VTE recurrence; Appropriately use anticoagulant therapy for the treatment of thrombosis
3 MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal Medicine, Department of Medicine, NYGH
4 Faculty/Presenter Disclosure Faculty Name: Benjamin Bell Relationships with commercial interests: Consulting Fees/Honoraria: Sanofi-Aventis Officer, Director, Or In Any Other Fiduciary Role: None Clinical Trials: None Ownership/Partnership/Principal: None Intellectual Property Rights: None Other Financial Benefit: None
5 Disclosure of Commercial Support This program has received financial support from Bayer Canada in the form of an educational grant. This program has been created solely by Thrombosis Canada without the input of any commercial or non-commercial organization Potential for conflict(s) of interest: Bayer Canada benefits from the sale of a product(s) that will be discussed in this program: Xarelto (rivaroxaban)
6 Mitigating Potential Bias This program has been created solely by Thrombosis Canada, a registered non-profit, non-commercial organization This program has been peer reviewed by Thrombosis Canada and the College of Family Physicians of Canada No commercial or other non-commercial organization have had any input to the content of this program No commercial or other non-commercial organization have been present at or privy to any discussions, meetings, or other activities related to the content of this program
7 Module 1: Learning Objectives After attending this session, participants will be better able to: Understand the risk of atrial fibrillation associated stroke; Identify patients with atrial fibrillation requiring anticoagulation based on stroke risk stratification; Use the most appropriate therapy to prevent stroke in patients with atrial fibrillation; Minimize bleeding risk in patients with atrial fibrillation requiring anticoagulation.
8 Case #1: Mrs. JM 77-year-old retired teacher Long standing atrial fibrillation Co-morbidity Type 2 diabetes Hypertension No other manifest vascular disease No major bleeding risk factors Chronic obstructive pulmonary disease (COPD) with frequent exacerbations requiring antibiotics Managed with warfarin Difficult to maintain in therapeutic range
10 STROKE: INCIDENCE AND ETIOLOGY
11 The Impact of Stroke Globally 1 : The 3 rd most common cause of death in developed countries 15 million strokes annually 5 million deaths 5 million people permanently disabled Each year in Canada 2 : 50,000 people have a stroke one every 10 minutes 14,000 people die from stroke the 3 rd leading cause of death Stroke costs the Canadian economy $2.7 billion annually 3 1. World Health Organization Heart and Stroke Foundation of Canada Press release. 3. Canadian Stroke Network.
12 Stroke Types and Incidence Cryptogenic 30% Other 5% Hemorrhagic stroke 12% Atherosclerotic cerebrovascular disease 20% Cardiogenic embolism 20% Small vessel disease lacunes 25% Ischemic stroke 88% Albers GW et al. Chest. 2004; 126(3 Suppl):438S-512S. Thom T et al. Circulation. 2006; 113(6):e85-e151.
13 ATRIAL FIBRILLATION RATES AND STROKE ASSOCIATION
14 Atrial fibrillation affects approximately 350,000 Canadians
15 Atrial Fibrillation A Growing Burden Go AS, et al. JAMA. 2001;285(18):
16 Atrial Fibrillation Major Risk Factor for Stroke Increases the risk of stroke by 5-fold 1,2,3 Accounts for approximately 15-20% of all strokes nationally 1,4 Associated with a 50-90% increase in mortality risk after adjustment for co-existing cardiovascular conditions 2 Risk of stroke in atrial fibrillation patients who do not receive anticoagulation averages ~ 5% per year Risk of stroke in atrial fibrillation patients by age group 1.5% in year olds 23.5% in year olds 1. Arch Intern Med 1994; 154(13): Wolf PA et al. Stroke. 1991; 22(8): Savelieva I, et al. Ann Med. 2007; 39(5): Singer DE, et al. Chest. 2008; 133(6 Suppl):546S-592S..
17 Attributable Risk of Stroke 30 Atrial fibrillation prevalence Strokes attributable to Atrial fibrillation Percentage (%) Age range (years) Wolf PA et al. Stroke 1991; 22(8):983-8.
18 Incidence of Stroke or Non-Central Nervous System (CNS) Systemic Embolism According to Type of Atrial Fibrillation 0.04 Cumulative hazard rates Sustained Paroxysmal Number at risk Years 1.5 Paroxysmal Sustained 1,199 1, ,499 5,264 4, ,560 Hohnloser SH, et al. J Am Coll Cardiol. 2007; 50(22):
19 Atrial Fibrillation Patients Have Increased Post-Stroke Mortality and Morbidity 60 Mortality 50 Morbidity Case-fatality rate With AF Without AF Bedridden patients (%) % 23.7% 0 30 days 1 year 0 With atrial fibrillation Without atrial fibrillation Dulli DA. et al. Neuroepidemiology. 2003; 22(2): Marini C. et al. Stroke. 2005; 36(6):
20 ATRIAL FIBRILLATION RELATED STROKE: RISK ASSESSMENT AND GUIDELINES
21 Predictive Index for Stroke CHADS 2 Risk Factor Score Congestive Heart Failure 1 Hypertension 1 Age 75 1 Diabetes Mellitus 1 Stroke/TIA/ Thromboembolism Maximum Score 6 2 Patients (n = 1733) Adjusted Stroke Rate (%/yr) 95% CI CHADS 2 Score (1.2 to 3.0) (2.0 to 3.8) (3.1 to 5.1) (4.6 to 7.3) (6.3 to 11.1) (8.2 to 17.5) (10.5 to 27.4) 6 Cairns et al, CanJ Cardiol. 2011;27: 74-90
22 Predictive Index for Stroke CHADS 2 CHA 2 DS 2 -VASc Risk Factor Score Risk Factor Score Congestive Heart Failure 1 Hypertension 1 Age 75 1 Diabetes Mellitus 1 Stroke/TIA/ Thromboembolism Maximum Score 6 2 Congestive Heart Failure 1 Hypertension 1 Age 75 2 Diabetes Mellitus 1 Stroke/TIA Thromboembolism Vascular Disease 1 Age Female 1 Maximum Score 9 Cairns et al. Can J Cardiol. 2011;27:
23 Bleeding Risk HAS-BLED Score Letter Clinical Characteristic Points H Hypertension 1 A Abnormal Liver or Renal Function / 1 point each 1 or 2 S Stroke 1 B Bleeding 1 L Labile INRs 1 E Elderly (age > 65 yr) 1 D Drugs or Alcohol / 1 point each 1 or 2 Maximum 9 points Pisters R, et al. Chest. 2010;138(5):
24 Bleeding Risk Management Address reversible risk factors: Falling provide mobility aid Hypertension treat BP to target Alcohol encourage abstinence Labile INR use NOAC Drugs replace NSAID with other analgesic, avoid ASA unless clearly indicated for secondary prevention GI bleeding use PPI Do not withhold anticoagulation unless bleeding risk extreme
25 Risks of a Fall While on Coumadin So... Absolute risk of subdural hematoma: Would need to fall 295 times a year to outweigh the benefits of 0.04%/yr warfarin (regardless of age/baseline stroke risk) Average RR of subdural # of falls hematoma in a fall risk in someone who falls vs someone who doesn t: 1.81/yr (Tinetti et al. N Engl J Med. 1988) 1.4 RR of subdural hematoma in faller on warfarin vs faller not on warfarin: 3.3 Man-Son-Hing M, et al. Arch Intern Med. 1999;159:
27 Assessing the Risk of Stroke > Age 65? Any other risk factor for stroke? Prior stroke? Diabetes? Anticoagulant indicated Hypertension? Female with vascular disease? Heart Failure? Adapted from: Skanes AC, et al.. Can J Cardiol. 2012;28(2):
29 NOVEL ORAL ANTICOAGULANTS FOR SPAF
30 Atrial Fibrillation Warfarin Benefit Warfarin reduces the risk of AF related stroke by about 2/3 Hart RG., et al. Ann Intern Med. 2007;146: Connolly S., et al. Lancet. 2006;367:
31 Treatment on Admission With Stroke All High-Risk Atrial Fibrillation Patients High-Risk Atrial Fibrillation Patients with Previous Stroke or Transient Ischemic Attack 2% 29% 3% 25% 29% 10% 15% 18% 29% 39% No antithrombotics Dual antiplatelets Single antiplatelet Warfarin: therapeutic Warfarin: sub-therapeutic Gladstone DJ. et al. Stroke. 2009; 40(1):
32 1 Million Preventable Strokes 15 million strokes annually worldwide 20% of strokes due to atrial fibrillation 1,2 2 million are preventable with warfarin therapy 50% of eligible patients treated with warfarin 4 1. Arch Intern Med Singer DE et al. Chest 2008; 133(6 Suppl):546S-592S. 3. Hart RG et al. Ann Intern Med 2007; 147(8): Connolly SJ et al. Circulation 2007; 116(4): million are due to atrial fibrillation Relative risk reduction (RRR) of 64% with warfarin 3 1 million strokes could have been prevented
33 RE-LY ROCKET-AF ARISTOTLE
34 Trials Comparing New Oral Anticoagulants vs Warfarin No. of patients Design RE-LY 1 ROCKET AF 2 ARISTOTLE 3 18,113 14,264 18,201 Non-inferiority, open label Non-inferiority, double blind Non-inferiority, double blind Study drugs Dabigatran (2 doses, blinded) Rivaroxaban Apixaban Control Open-label warfarin (INR 2 3) Double-blind warfarin (INR 2 3) Double-blind warfarin (INR 2 3) Primary Dose(s) Studied 110 mg BID and 150 mg BID 20 mg OD 5 mg BID Adjusted Dose Studied None 15 mg OD For patients with CrCl = ml/min 2.5 mg BID For patient with any two of the following: - Age 80 years - Body weight 60 kg - Serum creatinine 1.5 mg/dl (133 µmol/l) 1. Connolly SJ et al. N Engl J Med 2009;361: Patel MR et al. N Engl J Med 2011;365: Granger CB et al N Engl J Med 2011; 365: Patel MR et al, 2011; 2. Connolly SJ et al, 2009; 3. Lopes RD et al, 2010; 4.Granger CB et al, 2011.
35 Dabigatran: RE-LY Primary Outcome 150 mg RR = 0.55 (95% CI ) p < (superiority) p < (non-inferiority) 110 mg RR = 0.91 (95% CI ) p = 0.34 (superiority) p < (non-inferiority) Connolly SJ, et al. N Engl J Med. 2009;361:
36 Dabigatran: RE-LY Bleeding Connolly SJ, et al. N Engl J Med. 2009;361:
37 Rivaroxaban ROCKET-AF Primary Outcome Patel MR, et al. N Engl J Med. 2011; 365:883-91, ITT Analysis HR = 0.88 (95% CI ) p < (non-inferiority) p = 0.12 (superiority)
38 Rivaroxaban ROCKET-AF Bleeding Patel MR, et al. N Engl J Med. 2011; 365:883-91,
39 Apixaban ARISTOTLE Primary Outcome Granger CB et al. N Engl J Med :981-92,
40 Apixaban ARISTOTLE Bleeding Granger CB et al. N Engl J Med :981-92,
41 Apixaban & Bleeding Interesting results from AVERROES 55% reduction in the risk stroke and systemic embolism Comparable risk of major bleeding Connolly SJ, et al. N Engl J Med. 2011;364:
42 NOVEL ORAL ANTICOAGULANTS FOR SPAF DOSING
43 Canadian Dosing Recommendations for Stroke Prevention in AF Rivaroxaban Dabigatran Apixaban Patient has risk factor for stroke Estimate CrCl <30 ml/min ml/min >50 ml/min Contraindicated Elderly and/or risk factors for bleeding Age <75 years One other risk factor for bleeding Age years Age >80 years Recommended dose Dose can be considered 110mg BID 150mg BID 150mg BID 110mg BID 150mg BID 110mg BID Figure adapted from Huisman et al. Thromb Haemost 2012: 107: ,. Pradaxa PM November, 2012;
44 Canadian Dosing Recommendations for Stroke Prevention in AF Rivaroxaban Apixaban Patient has risk factor for stroke Dabigatran Estimate CrCl <30 ml/min ml/min >50 ml/min Recommended dose Not recommended 15 mg OD 20 mg OD *Rivaroxaban 15mg and 20mg should be taken with food Figure adapted from Huisman et al. Thromb Haemost 2012: 107: Xarelto PM, June 2013
45 Canadian Dosing Recommendations for Stroke Prevention in AF Rivaroxaban Apixaban Dabigatran Patient has risk factor for stroke Estimate CrCl <15 ml/min ml/mi n 25 ml/min Not recommended No dosing recommendation can be made* Check Age 80 years Check Weight 60 kg Check Serum Creatinine 133 micromol/l Recommended dose 2.5 mg BID If 2 features If 1 features 5 mg BID * In patients with ecrcl ml/min, no dosing recommendation can be made as clinical data are very limited Figure adapted from Huisman et al. Thromb Haemost 2012: 107: , Eliquis PM November, 2012;
46 Thrombosis Canada Antithrombotic Algorithm
47 Appropriate Candidates for Warfarin Severe renal impairment (CrCl < 25 ml/min) Patients with mechanical valve, rheumatic mitral valve disease Stable INR Patient preference Drug Cost: May impact some patients CCS 2012 AF Guidelines. Can J Cardiol ;28: ; Schulman S, Crowther MA. Blood 2012:119: ; Kirsch B. Managed Care Feb
48 Take-home Messages Atrial fibrillation is the most common significant cardiac rhythm disorder Atrial fibrillation is a major independent risk factor for ischemic stroke Current stroke prevention management in atrial fibrillation is poor Although warfarin is an effective agent to prevent AF stroke NOACs offer significant advantages in efficacy, safety and convenience
49 Atrial Fibrillation Strokes are NOT Cerebrovascular ACCIDENTS They are PREDICTABLE and PREVENTABLE Events
50 MODULE 2: Clinical Challenges in the Treatment of Venous Thromboembolism Menaka Pai, BSc, MSc, MD, FRCPC, ABIM Specialty: Hematology Assistant Professor, Department of Medicine, McMaster University Consultant Laboratory Hematologist, Hamilton Regional Laboratory Medicine Program, Supervising Hematologist, Hamilton General Core Laboratory, Hamilton, ON
51 Faculty/Presenter Disclosure Faculty Name: Menaka Pai Relationships with commercial interests: Consulting Fees/Honoraria: None Officer, Director, Or In Any Other Fiduciary Role: None Clinical Trials: Local PI for study funded by Bayer Ownership/Partnership/Principal: None Intellectual Property Rights: None Other Financial Benefit: None
52 Disclosure of Commercial Support This program has received financial support from Bayer Canada in the form of an educational grant This program has been created solely by Thrombosis Canada without the input of any commercial or non-commercial organization Potential for conflict(s) of interest: Bayer Canada benefits from the sale of a product(s) that will be discussed in this program: Xarelto (rivaroxaban)
53 Mitigating Potential Bias This program has been created solely by Thrombosis Canada, a registered non-profit, non-commercial organization This program has been peer reviewed by Thrombosis Canada and the College of Family Physicians of Canada No commercial or other non-commercial organization have had any input to the content of this program No commercial or other non-commercial organization have been present at or privy to any discussions, meetings, or other activities related to the content of this program
54 Module 2: Learning Objectives After attending this session, participants will be better able to: Use the most appropriate therapy to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) Uncomplicated DVT in the setting of a transient risk factor Unprovoked DVT Provoked PE stable and unstable patients Challenging clinical situations, including superficial thrombophlebitis, cancer-associated VTE, pregnancy-associated VTE, splanchnic thrombosis, upper extremity DVT Evaluate the risks and benefits of novel and traditional anticoagulants in patients with DVT and PE
55 Case #1: Deep Vein Thrombosis in a Surgical Inpatient A 75 year old, otherwise healthy man falls and sustains an intertrochanteric left hip fracture. He waits in hospital for 4 days before undergoing an open reduction internal fixation On postoperative day #2, nursing staff note that his left leg is swollen, erythematous and tender A duplex ultrasound confirms an occlusive deep vein thrombosis extending from the popliteal vein to the common femoral vein
56 Case #1: Deep Vein Thrombosis in a Surgical Inpatient What treatment options will you offer in the short and medium terms?
57 45,000 Canadians are affected by DVT each year. Why do we treat it? Prevent embolization Prevent extension Prevent recurrence Galanaud JP, et al. Thromb Haemost. 2009;102(3):493.
58 Systematic Review: Recurrent VTE in First 3 Months on Anticoagulants Outcome Patients with any VTE + Patients with DVT Patients with PE Patients, n Recurrent fatal VTE (95% CI), % 0.4 ( ) 0.3 ( ) 1.3 ( ) Recurrent PE (95% CI), % 1.6 ( ) 1.3 ( ) 3.0 ( ) Recurrent VTE (95% CI), % 3.4 ( ) 3.2 ( ) 3.6 ( ) + Patients presenting with DVT, PE or both or patients whose initial presentation was not specified in original study reports Carrier M., et al. Ann Intern Med. 2010;152(9):
59 Systematic Review: Bleeding in First 3 Months on Anticoagulants Outcome Patients with any VTE + Patients with DVT Patients with PE Patients, n Fatal major bleeding event (95% CI), % Major bleeding event (95% CI), % 0.2 ( ) 0.2 ( ) 0.2 ( ) 1.6 ( ) 1.6 ( ) 1.8 ( ) + Patients presenting with DVT, PE or both or patients whose initial presentation was not specified in original study reports Carrier M., et al. Ann Intern Med. 2010;152(9):
60 Initial Pharmacologic Therapy of Uncomplicated DVT Unfractionated heparin (UFH) Low molecular weight heparin (LMWH) Fondaparinux Oral factor Xa inhibitors Rivaroxaban Apixaban Oral direct thrombin inhibitors Dabigatran
61 Traditional Anticoagulants: Pros and Cons Unfractionated Heparin Use is complicated by narrow therapeutic range, inter-individual variation in anticoagulant effect, and increased risk of heparin induced thrombocytopenia (HIT) Ideal in patients with: severe renal insufficiency (CrCl < 30 ml/min) patients at increased risk for bleeding, in whom rapid reversal of the anticoagulant effect may be needed patients who receive thrombolytic therapy Initial treatment with UFH is generally a segue to therapeutic dose warfarin (INR 2-3)
62 Traditional Anticoagulants: Pros and Cons LMWH Use is complicated by inconvenient route of administration (subcutaneous), cost When compared to UFH, it is more bioavailable, has predictable dosing, has longer duration of effect, has lower risk of HIT, has less effect on bone metabolism, and no requirement for monitoring Ideal in patients with: cancer who require long-term anticoagulation Initial treatment with LMWH is generally a segue to therapeutic dose warfarin (INR 2-3)
63 Traditional Anticoagulants: Pros and Cons Fondaparinux Has many of the same advantages and disadvantages of LMWH Double-blind, randomized MATISSE trial randomized 2205 patients with acute symptomatic DVT to: fondaparinux (5, 7.5, or 10 mg subcutaneously once daily for weights of <50, 50 to 100, or >100 kg, respectively) enoxaparin (1 mg/kg subcutaneously twice daily) for at least five days, and until vitamin K antagonists were therapeutic with INR > 2 Fondaparinux is at least as effective and safe as enoxaparin for initial treatment of DVT
64 Novel Oral Anticoagulants (NOACs) Pharmacological Properties Characteristic Rivaroxaban 1 Dabigatran 2 Apixaban 3 Target Factor Xa Factor IIa Factor Xa Prodrug No Yes No Dosing OD BID BID Bioavailability, % %* 6.5% 50% Half-life 5-13h h 8-15 h Renal clearance (unchanged bioavailable drug) ~33% 85% 27% Cmax 2-4 h 1-2 h 3-4 h Drug interactions Strong inhibitors of both CYP3A4 and P-gp P-gp inhibitors * When the 15mg and 20mg dose is taken with food Factoring in the absolute bioavailability of apixaban, ~ 50 % of the systemically available dose is eliminated in urine Strong inhibitors of both CYP3A4 and P-gp 1. Xarelto PM, June 2013; 2. Pradaxa PM November, 2012; 3. Eliquis PM November, 2012; 4. FDA Eliquis Drug Approval Package, Clinical Pharmacology/Biopharmaceutics Review
65 Major Trials Comparing NOACs to Warfarin in VTE EINSTEIN-DVT 1 EINSTEIN-PE 2 AMPLIFY 3 No. of patients (acute, symptomatic DVT) (acute, symptomatic PE with or without DVT) (acute VTE) Design Non-inferiority, open label Non-inferiority, open label Non-inferiority, double blind Study Drug Rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg once daily Rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg once daily Apixaban 10 mg twice daily for 7days followed by 5 mg twice daily Control Subcutaneous enoxaparin followed by a VKA (warfarin or acenocoumarol) Subcutaneous enoxaparin followed by a VKA (warfarin or acenocoumarol) Subcutaneous enoxaparin for 5 days followed by warfarin Primary efficacy outcomes Recurrent VTE Recurrent VTE Recurrent symptomatic VTE or death related to VTE Primary safety outcomes Major bleeding or clinically relevant non-major bleeding Major bleeding or clinically relevant non-major bleeding Major bleeding or clinically relevant non-major bleeding 1. Bauersachs R, et al. N Engl J Med. 2010;363(26): Büller HR, et al. N Engl J Med. 2012;366(14): AMPLIFY Investigators, et al. N Engl J Med. 2013;369(9):
66 Major Trials Comparing NOACs to Warfarin in VTE RE-COVER 4 HOKUSAI-VTE 5 No. of patients Design Study Drug Control Primary efficacy outcomes Primary safety outcomes (acute PE) Non-inferiority, double blind Dabigatran 150 mg bid Double-blind warfarin (INR 2 3) Recurrent symptomatic, VTE and related deaths Bleeding events, acute coronary syndromes, other adverse events, results of liver-function tests (acute, symptomatic PE with or without DVT) Non-inferiority, double blind Heparin (enoxaparin or UFH) followed by edoxaban 60 mg daily (or 30 mg daily if CrCl ml/min or wt < 60 kg) Heparin (enoxaparin or UFH) followed by warfarin Recurrent symptomatic VTE Major bleeding or clinically relevant nonmajor bleeding 4. RE-COVER Study Group, et al. N Engl J Med. 2009;361(24): Hokusai-VTE Investigators, et al. N Engl J Med
67 How Do NOACs Stack Up to Warfarin? 2012 Meta-analysis of 9 randomized trials concluded: Compared with VKAs, NOACs had similar risk of recurrence of acute VTE and all cause mortality, though rivaroxaban was associated with a reduced risk of bleeding Compared with each other, no one NOAC was superior to any other in terms of recurrent VTE, mortality or major bleeding Subsequent studies suggest apixaban and edoxaban also associated with a reduced risk of bleeding Further trials and postmarketing surveillance are needed for all of the NOACs Fox BD, et al. BMJ. 2012;345:e7498.
68 Relative Risk for Recurrent VTE with Novel Oral Anticoagulants vs Vitamin K Antagonists Fox BD, et al. BMJ. 2012;345:e by British Medical Journal Publishing Group
69 Relative Risk for Major Bleeding with NOACs vs VKAs Fox BD, et al. BMJ. 2012;345:e by British Medical Journal Publishing Group
70 Relative Risk for All-Cause Mortality with NOACs vs VKAs Fox BD, et al. BMJ. 2012;345:e by British Medical Journal Publishing Group
71 Pros and Cons of NOACs Rapid onset Predictable effect Specific target Few food / drug interactions Renal elimination Difficult to monitor Potential for overuse High cost Short half-life No antidote
72 Which Agent to Choose? Consider patient's values and preferences Risk tolerance for bleeding versus clotting Ability to afford drug Ability to get lab work done Need to affiliate closely with healthcare providers Consider patient's bleeding risk factors Age, previous bleeding, cancer, renal failure, liver failure, thrombocytopenia, anemia, previous stroke, diabetes, antiplatelet therapy, poor anticoagulant control, co-morbidity and reduced functional capacity, recent surgery, frequent falls, alcohol abuse
73 If You Choose a NOAC for VTE Rivaroxaban Health Canada approved for treatment of DVT without symptomatic PE and for treatment of PE Recommended dosing is 15 mg twice daily for first 21 days, followed by 20 mg once daily for duration of treatment Overlap with a parenteral agent not needed Should not be used in women who are pregnant or breast-feeding. Dabigatran Not Health Canada approved for treatment of DVT or PE
74 Rivaroxaban : Only Currently Approved NOAC for VTE Treatment Straightforward oral treatment option for DVT and PE Ideal for primary care physicians who... Are not comfortable with the use of LMWH Do not have the necessary time and resources to teach patients self-injection Benefits of Rivaroxaban in treatment of VTE Stable patients can be treated in the primary care setting, without referral to emergency rooms More rapid treatment initiation No overlap with LMWH or UFH required Greater convenience for patient and physician Potentially reduced health care costs
75 Case #2: Deep Vein Thrombosis In an Outpatient A 45 year old man with a past history of hypertension and seasonal allergies presents to his family doctor with a swollen, erythematous and tender left leg. He reports no recent changes in his health or activities. He is on hydrochlorothiazide and ceterizine. The nearest lab is closed, so a duplex ultrasound is not available
76 Case #2: Deep Vein Thrombosis In an Outpatient What treatment options will you offer? If an ultrasound is not rapidly available patients with moderate to high suspicion of DVT, and a low to moderate risk of bleeding, should start therapy before the diagnosis is confirmed!
77 Case #2: Deep Vein Thrombosis In an Outpatient The patient returns for an ultrasound the following morning. A duplex ultrasound confirms an occlusive deep vein thrombosis extending from the popliteal vein to the common femoral vein
78 Case #2: Deep Vein Thrombosis In an Outpatient What treatment options will you offer? What duration of treatment is required?
79 Duration of Therapy Categories of VTE Isolated distal DVT, DVT or PE provoked by a transient risk factor First unprovoked DVT or PE Duration of Treatment 3 months Minimum of 3 months and then reassess. For patients with no or only minor risk factors for bleeding, long-term therapy with annual review can be offered. Decision to continue anticoagulation should consider patient s values and preferences. Second unprovoked DVT or PE Cancer-associated VTE Minimum of 3 months and then reassess. For patients with no or only minor risk factors for bleeding, long-term therapy with annual review should be encouraged. Decision to continue anticoagulation should consider patient s values and preferences. Minimum of 3 months and then reassess. Continue if active cancer (overt evidence of cancer) or continuing to receive anti-cancer therapy Schulman S, et al.. N Engl J Med. 1995;332(25):1661.
80 Decisions About Duration of Therapy Must Consider Bleeding and Thrombosis Risk, as well as Patient s Values and Preferences Transient risk factors include: surgery, hospitalization or plaster cast immobilization, all within 3 months, lesser leg injuries or immobilizations more recently (e.g. within 6 weeks), estrogen therapy or pregnancy, prolonged travel (e.g. > 8 hours) Bleeding risk factors include: Age, previous bleeding, cancer, renal failure, liver failure, thrombocytopenia, anemia, previous stroke, diabetes, antiplatelet therapy, poor anticoagulant control, co-morbidity and reduced functional capacity, recent surgery, frequent falls, alcohol abuse
81 Long-term Therapy with NOACs EINSTEIN-EXTENSION: compared to placebo, rivaroxaban associated with less recurrent DVT, more clinically relevant nonmajor bleeding, and similar nonfatal major bleeding after 6 to 12 months of therapy AMPLIFY-EXT: compared to placebo, apixaban (prophylactic or therapeutic dose) associated with less recurrent VTE after 6 months of therapy RE-MEDY: compared to warfarin, dabigatran associated with similar rate of recurrent VTE, less major or clinically relevant bleeding, and more acute coronary syndrome after at least 3 months of therapy RE-SONATE: compared to placebo, dabigatran associated with less recurrent VTE, and more major or clinically relevant bleeding after at least 3 months of therapy
82 Rivaroxaban: An Approved NOAC for Long-term VTE Treatment At this time, Rivaroxaban can be used for long-term treatment of both DVT and PE EINSTEIN-EXTENSION trial provides supporting evidence Patients should be counselled on increased risk of clinically relevant non-major bleeding
83 What about acetylsalicylic acid (ASA) for long-term therapy? Two studies compared 100 mg ASA to placebo in patients with first unprovoked DVT who completed 6-18 months of anticoagulation Pooled analysis showed that patients on ASA had: 32% reduction in VTE recurrence (p=0.007) 34% reduction in other major vascular events (e.g., ACS, stroke) (p=0.002) No significant increase in major or clinically significant bleeding ASA should not be used for initial treatment of DVT ASA likely provides less benefit than continued anticoagulation for extended treatment! Becattini C, et al. N Engl J Med. 2012;366(21): Brighton TA, et al. N Engl J Med. 2012;367(21):
84 Case #3: Pulmonary Embolism in an Outpatient A 25 year old woman with a past history of mild asthma presents to the emergency room with sharp chest pain, worsened on deep inspiration. Vital signs are stable, and peripheral oxygen saturations are 99% on room air. Her D- dimer is markedly elevated (>3000). She reports starting a combined oral contraceptive pill 30 days ago. CT-PA shows bilateral pulmonary emboli.
85 Case #3: Pulmonary Embolism in an Outpatient What treatment options will you offer? What duration of treatment is required? Can this patient be sent home?
86 Case #3: Pulmonary Embolism in an Outpatient What treatment options will you offer? Rivaroxaban Warfarin (with initial overlap with subcut LMWH or IV UFH, until INR > 2) What duration of treatment is required? PE in the setting of a transient risk factor Must treat for a minimum of 3 months Can discontinue anticoagulation at 3 months if patient discontinues estrogen-containing products Can this patient be sent home? YES!
87 Do I need to consider thrombolytic therapy? Paucity of evidence Patients with acute PE and signs of hemodynamic compromise suggesting right heart failure are at increased risk of early mortality They should be considered for systemic thrombolysis May reduce mortality May increase risk of major bleeding including 2% risk of intracranial hemorrhage
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.firstname.lastname@example.org This presentation will discuss unlabeled and investigational use of products The author
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
+ New oral anticoagulants: A review of current indications November 2 nd, 2012 Dr. Sudeep Shivakumar, Hematology Dalhousie University + Objectives es To review indications for anticoagulation To discuss
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
Home treatment of VTE Prof. Adel El-Etriby Ain-Shams University Venous Thromboembolism (VTE): The DVT and PE Continuum Migration Embolus Thrombus VTE refers to a continuum of disease that begins with DVT
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
Anticoagulation at the end of life Rhona Maclean Rhona.email@example.com Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2016 Origination: 6/2014 Next Review: 7/2017 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto when
Conflict Disclosure Information Kevin J. Pistawka NOAC S New Oral Anti-Coagulants Dr. K. Pistawka - KGH FINANCIAL DISCLOSURE Grants/Research Support: None Research Trial involvment RELY, RELYABLE Speakers
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
De afbeelding kan niet worden weergegeven. Mogelijk is er onvoldoende geheugen beschikbaar om de afbeelding te openen of is de afbeelding beschadigd. Start de computer opnieuw op en open het bestand opnieuw.